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ABSTRACT 
Haemophagocytic syndrome, or haemophagocytic lymphohistiocytosis (HLH), is a 
hyperinflammatory disorder characterised by uncontrolled activation of the immune 
system.  It can result from mutations in multiple genes involved in cytotoxicity or 
occur secondary to a range of infections, malignancies or autoimmune rheumatic 
diseases.  In the latter case it is also known as macrophage activation syndrome 
(MAS).  Characteristic features are persistent fever, hepatosplenomegaly, 
petechial/purpuric rash, progressive cytopenias, coagulopathy, transaminitis, raised 
C-reactive protein, falling erythrocyte sedimentation rate, hypertriglyceridaemia, 
hypofibrinogenaemia, and extreme hyperferritinaemia often associated with multi-
organ impairment.  Distinguishing HLH from systemic sepsis can present a major 
challenge.  Criteria for diagnosis and classification of HLH and MAS are available 
and a serum ferritin > 10,000 µg/L is strongly supportive of HLH. Without early 
recognition and appropriate treatment, HLH is almost universally fatal. However, with 
prompt referral and advancements in treatment over the past two decades, 
outcomes have greatly improved. 
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INTRODUCTION 
 
Haemophagocytic syndrome, also known as haemophagocytic lymphohistiocytosis 
(HLH), is a rare but potentially fatal multi-system inflammatory disorder characterised 
by uncontrolled hyperactivation of macrophages (histiocytes) and T lymphocytes.  
Primary HLH is a genetic disease resulting from recessive defects in the cytolytic 
pathway of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs).[1]  It 
predominantly affects children, although onset in adulthood has been reported.[2]  
Secondary, or acquired, HLH is triggered by a wide variety of infections, 
malignancies and autoimmune diseases.  Secondary HLH in the context of 
rheumatic diseases, such as systemic juvenile idiopathic arthritis (sJIA), is often 
designated macrophage activation syndrome (MAS).[3 4]  Although termed 
“secondary”, on some occasions HLH can be the presenting manifestation of the 
underlying condition in a previously-well child.  It can be difficult to distinguish from 
systemic sepsis or autoimmune diseases.[5 6]  Given the risk of significant morbidity 
and mortality, recognition of HLH/MAS and its early management are important skills 
for all paediatricians.    
 
The purpose of this article is to raise awareness of HLH/MAS and provide a guide to 
its correct and early diagnosis.  It will also provide a summary of epidemiology, 
aetiology and pathogenesis.  For details on specific treatments of HLH and MAS, 
including immunosuppression, pro-apoptotic chemotherapy and haematopoietic 
stem cell transplantation, readers are referred to several recent reviews.[1 2 4] 
4 
 
CASE VIGNETTE * 
A previously-well, 3 year old Caucasian boy was referred to the Paediatric team with 
a fever and rash.  He had not been completely well for 2 weeks with coryza, sore 
throat and intermittent temperatures.  He had deteriorated over the previous week 
with a reduced appetite and a fluctuating, red blanching rash. There was no history 
of diarrhoea, vomiting, cough or altered consciousness. He had no significant past or 
family history, no regular medications or foreign travel.  Initial assessment showed a 
febrile, unwell child with heart rate 130/minute, blood pressure 96/55 mmHg, 
respiratory rate 40/minute, oxygen saturations 97% in air and temperature 39°C.  He 
had a blanching, macular, erythematous rash on his torso and upper legs, coryza, a 
red throat but without exudate and several moderately enlarged cervical lymph 
nodes.  There was poorly-localised, mild abdominal tenderness and a palpable liver 
edge.  Complete examination of the musculoskeletal system revealed no signs of 
arthritis.  Cardiovascular, respiratory and neurological examinations were normal.   
 
Initial investigations were performed including blood and urine cultures, bacterial and 
viral throat swabs, anti-streptolysin O titre (ASOT) and Epstein-Barr virus (EBV) 
serology.  Baseline blood results are shown in Table 1. He was clinically felt to be 
septic and was commenced on intravenous ceftriaxone.  He was also given 
intravenous fluids due to poor oral intake.   
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Table 1: Laboratory parameters at presentation and during admission 
Laboratory parameter At presentation Day 3 
Haemoglobin (g/L) 101 84 
White blood cells (x 109 /L) 21.2 12.2 
Neutrophils (x 109 /L) 15.4 4.4 
Platelets (x 109 /L) 505 90 
Sodium (mmol/L) 134 133 
Potassium (mmol/L) 4.8 5.9 
Urea (mmol/L) 8.1 20.2 
Creatinine (mmol/L) 41 96 
Bilirubin 34 78 
Albumin 37 24 
ALP (IU/L) 440 620 
ALT (IU/L) 32 120 
AST (IU/L) n/d 170 
LDH (IU/L) n/d 1700 
Fasting triglycerides n/d 3.2 mmol/L (283mg/dL) 
CRP (mg/L) 90 205 
ESR (mm/h) n/d 24 
Ferritin (µg/L) n/d 9080 
PT (s) n/d 20 
APTT (s) n/d 41 
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Fibrinogen (mg/dL) n/d 90 
D-dimer (ng/mL) n/d 1240 
Legend: ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated 
partial thromboplastin time; AST, aspartate aminotransferase; CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; PT, 
prothrombin time. 
Figures in bold highlight changes in parameters which are concerning and 
suggestive of progression to HLH. 
 
 
 
Over the next 48 hours he continued to have fevers over 38°C and results of blood 
and urine cultures yielded no growth.  EBV viral capsid antigen (VCA) IgM and IgG 
were positive suggesting a recent infection.  On the third day of admission he 
appeared to be clinically deteriorating with lethargy, petechial rash, cool peripheries, 
tachycardia and reduced urine output.  Repeat blood tests are shown in Table 1 with 
concerning changes, consistent with HLH, highlighted in bold.  
 
Recognising the features of persisting fever, multi-organ involvement (renal, hepatic 
and potentially neurological), cytopenias, coagulopathy and increasing CRP despite 
treatment with a broad spectrum antibiotic, the diagnosis of HLH was considered.  
The child was managed in a high dependency environment and appropriate 
emergency resuscitation and stabilisation treatment instituted.  He was discussed 
with the Paediatric Intensive Care team at the local tertiary hospital. Additional 
investigations were requested including: erythrocyte sedimentation rate (ESR), 
7 
 
ferritin, fasting triglycerides, fibrinogen, D-dimers, lactate dehydrogenase and 
aspartate aminotransferase (AST).  The results are shown in Table 1. 
 
EPIDEMIOLOGY 
Primary, or genetic, HLH is a rare disease with an estimated incidence of 
0.12/100,000 children per year in a Swedish study [7] and 0.34/100,000 children per 
year in studies from Japan.[8]  The prevalence of all cases of HLH under 18 years of 
age has been estimated as 1.07/100,000.[9]  In general, however, HLH is under-
recognised and the true prevalence, particularly of secondary HLH, is likely to be 
higher.[10]  In the context of sJIA, MAS occurs in 7-13% of patients.[11] Evidence of 
subclinical MAS based on bone marrow findings was present in 53% of sJIA patients 
at diagnosis.[12]  
 
AETIOLOGY 
Primary HLH is of genetic origin and results from mutations in an increasing list of 
genes associated with the cytolytic and apoptotic pathways (Table 2, reviewed in 
[13]).  Although it is the more-likely form of disease to be seen in infants and very 
young children, mutations and potentially-pathogenic polymorphisms have been 
identified in older children and adults with apparently secondary (infection- or 
rheumatic disease-triggered) HLH.  Conversely, infections may be the trigger for 
active HLH even in young children with genetic mutations.  Therefore the distinction 
between “primary” and “secondary” may be blurred.   
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Table 2: Classification of genetic HLH [13] 
Disease name Gene Protein Function 
FHL1 Unknown - - 
FHL2 PRF1 Perforin Pore formation 
FHL3 UNC13D Munc 13-4 Vesicle priming 
FHL4 STX11 Syntaxin 11 Vesicle fusion 
FHL5 STXBP2 Munc 18-2 Vesicle fusion 
Griscelli syndrome 
type 2 
RAB27A Rab27a Vesicle docking 
Chediak-Higashi 
syndrome 
LYST Lyst Vesicle trafficking 
Hermansky Pudlak 
syndrome type 2 
AP3B1 AP3B1 Vesicle trafficking 
XLP1 SH2D1A SAP Signalling in T, NK and NK-T cells 
XLP2 XIAP XIAP Signalling pathways via NF-κB 
ITK deficiency ITK ITK Signalling in T cells 
CD27 deficiency CD27 CD27 Lymphocyte co-stimulatory molecule 
XMEN syndrome MAGT1 Magnesium 
transporter 1 
T cell activation via T cell receptor 
Legend: FHL, familial haemophagocytic lymphohistiocytosis; ITK, interleukin-2-
inducible T cell kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated 
B cells; NK, natural killer; SAP, signalling lymphocyte activation molecule (SLAM) 
associated protein; XIAP, X-linked inhibitor of apoptosis; XLP, X-linked 
lymphoproliferative syndrome; XMEN, X-linked immunodeficiency with magnesium 
defect, Epstein-Barr virus infection, and neoplasia.  
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Viruses are the most common aetiological agent for infection-triggered HLH with 
Epstein-Barr virus (EBV) being the precipitant in 74% of children where an infectious 
cause was identified.[14]  Of note, in male patients an association has been 
identified between EBV-associated HLH and X-linked lymphoproliferative syndromes 
types 1 (XLP1) and 2 (XLP2) and XMEN syndrome caused by mutations in the 
SH2D1A, XIAP and MAGT1 genes respectively.[13 15]   
 
Herpes simplex virus (HSV) has been recognised as a relatively common trigger for 
severe HLH in neonates.  It was identified as the cause in 30% in a case series 
(n=20) from Japan and was associated with a poor prognosis.[16]  Other viral 
triggers for HLH include cytomegalovirus (CMV), adenovirus, influenza A, Dengue 
and Ebola.[4 17]  Leishmaniasis can also be a cause for HLH with reports from a 
wide range of countries including within Europe.[18] 
 
Malignancies, particularly lymphomas and leukaemias, can be a trigger for HLH 
although less commonly in children than in adults.  In the younger age group, acute 
B-lymphoblastic leukaemia is the most-frequently associated malignancy.[10]  HLH 
may present before the underlying malignancy is detected and this should be 
considered during the diagnostic work-up. 
 
Among rheumatic diseases, secondary HLH/MAS is most frequently associated with 
sJIA.  It has also been reported in the context of Kawasaki disease, juvenile systemic 
lupus erythematosus (JSLE), polyarticular JIA, juvenile dermatomyositis, 
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antiphospholipid syndrome and mixed connective tissue disease.[4]  MAS can be 
triggered by a flare of the underlying disease or may be the first presentation of the 
rheumatic diagnosis.[19]  Methotrexate and biologic drugs used to treat the 
rheumatic disease have also been suspected as causing MAS in some cases.[20 21]  
Haemophagocytic syndrome is a recognised complication following haematopoietic 
stem cell transplantation used to treat severe JIA.[22 23] 
 
Immunodeficiency is a characteristic feature of some of the genetic diseases 
associated with primary HLH, such as Chediak-Higashi syndrome and Griscelli 
syndrome type 2.  Acquired immunosuppression, either iatrogenic or resulting from 
HIV infection, has also been identified as causing HLH.  It is not clear if this results 
from decreased immune surveillance or more frequent infections.[24] 
 
 
PATHOGENESIS 
During normal immune responses, cells of the innate immune system such as 
macrophages and dendritic cells are activated, via toll-like receptors, by molecules 
from micro-organisms called pathogen-associated molecular patterns (PAMPs).  
These cells phagocytose pathogens, present antigens and activate the adaptive 
immune system.  NK cells and CTLs recognise and destroy pathogen-infected cells 
via a cytolytic pathway by release of granules containing the lytic proteins perforin 
and granzymes.[1]  They also produce pro-inflammatory cytokines such as interferon 
gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α) which activate and recruit 
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macrophages to tissues.    NK cells and CTLs play a role in removal of antigen-
presenting cells (APCs) by inducing apoptosis, thus providing a form of negative 
feedback.[25]  
 
In genetic HLH, molecular defects in the cytolytic pathway result in failure of 
destruction of target infected cells and APCs which results in a “cytokine storm”.  
Elevated levels of TNF-α, interleukin 6 (IL-6), IL-1 and others cause high fever and 
infiltration of tissues with activated macrophages and lymphocytes, leading to multi-
organ inflammation and damage.[26]  
 
In acquired, non-genetic, forms of HLH it is infection, malignancy or autoimmune 
disease which the shifts the immune system balance.  In EBV-induced HLH, the 
infected B lymphocytes act as APCs and proliferate more rapidly than can be 
controlled by EBV-specific CTLs. The resulting immune system hyperactivation 
produces the clinical picture of HLH.[27]  
 
CLINICAL FEATURES AND DIAGNOSIS 
Critical to diagnosis of HLH is an awareness of the disease and a high degree of 
suspicion in children with some of the clinical features.  Each feature alone is non-
specific and may be caused by a wide range of diseases.  However the combination 
of clinical and laboratory signs, their severity and the changes over time facilitate 
correct diagnosis.  The characteristics which point to a diagnosis of HLH/MAS are 
shown in Table 3.  Many of these are also seen in severe systemic sepsis and some 
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consider HLH and severe sepsis to be phenotypes on a spectrum of 
hyperinflammatory reactions.[28]  The cardinal features of HLH are fever, 
hepatosplenomegaly and cytopenias, particularly with failure to respond to initial anti-
infective treatments.   
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Table 3: Clinical and laboratory features of HLH / MAS 
System Clinical features Laboratory features 
General Fevers Fall in ESR 
Raised CRP 
Elevated sIL-2Ra 
Haematological Coagulopathy 
Petechiae, 
purpura, 
ecchymoses 
Epistaxis 
 
Extreme 
hyperferritinaemia  
Leucopenia 
Anaemia 
Thrombocytopenia 
Haemophagocytosis 
and hypercellularity on 
bone marrow 
aspiration 
Central nervous system Altered mental 
state 
Seizures 
Encephalopathy 
Coma 
CSF pleiocytosis 
 
Gastrointestinal Haematemesis 
Rectal bleeding 
Liver dysfunction 
Hepatomegaly 
Splenomegaly 
Transaminitis 
Mildly elevated 
bilirubin 
Hypoalbuminaemia 
Normal or mildly 
raised ammonia 
Elevated triglycerides 
Renal - Abnormal renal 
function 
Respiratory ARD 
Pulmonary 
infiltrates 
- 
Legend: ARD, acute respiratory distress; CRP, C-reactive protein; CSF, 
cerebrospinal fluid; ESR, erythrocyte sedimentation rate; sIL-2Ra, soluble 
interleukin-2 receptor alpha chain (also known as sCD25). 
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HLH can affect all organ systems.  Neurological manifestations have been reported 
at presentation in up to 30% and include cranial nerve palsies, ataxia, 
encephalopathy and seizures.  Elevated cerebrospinal fluid (CSF) protein or cell 
count are found in approximately half of patients.[27]  In the neonatal age group, 
presentation of HLH may be with isolated CNS involvement or with fulminant liver 
failure.[29]  In the latter case it may be almost indistinguishable from neonatal 
haemochromatosis, although this is not associated with fever, cytopenias or 
hypertriglyceridaemia.[16] 
 
Diagnostic criteria for HLH were developed for the HLH-2004 study and are shown in 
Table 4.[30]  In a child with the appropriate acute clinical presentation, a diagnosis 
can be made on the basis of identification of mutations in HLH-associated genes or 
presence of 5 of 8 diagnostic criteria.  In children other than neonates, fever and 
splenomegaly are present in 90-100% at diagnosis of HLH.[31]  
 
Hyperferritinaemia is a crucial marker for active HLH/MAS.  It is an acute phase 
reactant and may be raised in several inflammatory or infective processes at a lower 
level.  However, ferritin > 10,000 µg/L in children was found to be 90% sensitive and 
96% specific for HLH.[32]  Figure 1 illustrates that ferritin can be a helpful test for 
stratifying patients with a systemic sepsis / HLH presentation. 
 
When considering other laboratory measures, such as cytopenias, transaminases 
and ESR, an important feature to recognise is that it is change in parameters over 
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time, rather than absolute values, which may indicate progression to HLH at an 
earlier stage.  For example, neutrophils and platelets may be within the laboratory 
normal range but it is the drop from previously elevated levels associated with acute 
infection or active autoimmune disease which may herald development of HLH.[33]  
The paradoxical falling ESR despite increasing systemic inflammation is thought to 
be secondary to decreasing fibrinogen resulting from fibrinogen consumption and 
liver dysfunction.[4]  Measuring ESR and CRP together is helpful: a dropping ESR 
coupled with persistently elevated or rising CRP is an important sign of HLH. 
 
A significant problem with the HLH-2004 criteria is that measurement of NK cell 
function and soluble interleukin 2 receptor alpha chain (sIL-2Ra, CD25) are available 
only in specialised immunology or research laboratories.  In addition, it may be 
inappropriate to undertake bone marrow biopsy under general anaesthetic in a 
critically unwell child with coagulopathy in order to detect haemophagocytosis.  While 
the presence of haemophagocytosis in bone marrow can help to confirm the 
diagnosis of HLH, it is frequently absent, particularly in the early stages.[34 35]  A 
multinational study of 362 patients with MAS complicating sJIA reported that only 
60.7% of patients whose bone marrow was examined showed haemophagocytosis 
[36].  The above tests, therefore, may be unavailable or non-diagnostic leading to 
critical delay in initiation of appropriate treatment. 
 
Partly because of these difficulties, one study used HLH-2004 criteria excluding 
those for NK cell function, sIL-2Ra level and tissue haemophagocytosis in sJIA 
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patients suspected of having MAS, therefore using thresholds of 3/5 or 4/5 criteria.  
These adapted HLH-2004 guidelines were found to have high specificity but low 
sensitivity for diagnosis of MAS associated with sJIA.[37]  A further problem in this 
context was the overlap in clinical features between HLH diagnostic guidelines and 
those seen the rheumatic conditions underlying MAS; this limits their usefulness in 
the paediatric rheumatology population.   
 
In order to address the specific difficulties of distinguishing active sJIA from MAS, 
consensus-derived classification criteria for MAS in sJIA have recently been 
published.[38]  These are summarised in Table 4.  The platelet count ≤ 181 x 109 /L 
and fibrinogen ≤ 3.6 g/L do overlap with the normal range, but it is these results in 
the context of a child with significant systemic inflammation which raise suspicion of 
MAS. 
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Table 4: Diagnostic criteria for HLH, classification criteria for MAS in sJIA and 
classification criteria for sJIA 
Revised 2004 Diagnostic Criteria for HLH a 2016 Classification of MAS in sJIA b 
EITHER: 
A. Molecular genetic confirmation 
OR 
B. Five of the following: 
1. Fever 
2. Splenomegaly 
3. At least 2 of: 
i Haemoglobin < 90 g/L 
ii Platelets < 100 x 109 /L 
iii Neutrophils < 1 x 109 /L 
4. Either of: 
i Fasting triglycerides ≥ 265 mg/dL (3.0 
mmol/L), OR 
ii Fibrinogen ≤ 1.5 g/L 
5. Ferritin ≥ 500 µg/L 
6. Tissue haemophagocytosis 
7. Decreased NK cell function 
8. sIL-2R ≥ 2400 U/ml 
A febrile patient with known or suspected 
sJIA with: 
1. Ferritin > 684 µg/L AND 
2. Any 2 of the following: 
 Platelets ≤ 181 x 109 /L 
 AST > 48 U/L 
 Triglycerides > 156 mg/dL (1.76 
mmol/L)  
 Fibrinogen ≤ 3.6 g/L 
ILAR Classification of sJIA c 
Arthritis in ≥ 1 joints with or preceded by 
fever for ≥ 3 days, accompanied by ≥ 1 of the 
following: 
• Evanescent erythematous rash 
• Generalised lymphadenopathy 
• Hepatomegaly and/or splenomegaly 
• Serositis 
AND exclusion of: A, B, C, D 
 
Exclusions: 
A: psoriasis, or history of psoriasis, in patient or first-degree relative 
B: HLA-B27 positive, male and older than 6 years 
C: Ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory 
bowel disease, Reiter syndrome or acute uveitis, or history of 1 of these in first-
degree relative 
D: Presence of IgM rheumatoid factor on ≥ 2 occasions ≥ 3 months apart 
 
Legend: AST, aspartate aminotransferase; HLH, haemophagocytic 
lymphohistiocytosis; ILAR, International League of Associations for Rheumatology; 
MAS, macrophage activation syndrome; NK, natural killer; sIL-2R, soluble 
interleukin-2 receptor; sJIA, systemic juvenile idiopathic arthritis 
a Based on Henter et al.[30]  b Based on Ravelli et al.[38]  c Based on Petty et al.[39] 
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Once HLH has been diagnosed, the underlying cause for the syndrome should be 
investigated including a search for genetic mutations.  Figure 2 provides an example 
algorithm which initially uses flow cytometry analysis to identify deficiencies in key 
proteins listed in Table 2.  Molecular genetic analysis, which may take several 
weeks, is subsequently used to confirm specific mutations.   
 
Infections may trigger HLH in patients both with and without genetic disease.  
Screening for viruses using polymerase chain reaction (PCR) including EBV, CMV, 
parvovirus B19, adenovirus, HSV, human herpes virus 6 and varicella zoster virus 
has been recommended.[27]  If a bone marrow biopsy is performed, a sample 
should also be send for PCR looking for leishmania infection. 
 
In patients with a known rheumatic disease who develop MAS, it is not yet clear 
whether screening tests for primary HLH are also necessary.  One study reviewed 
retrospectively 21 patients who presented with MAS and also had at least one 
primary HLH screening test (NK cell perforin expression; NK cell Granule Release 
Assay (GRA); anti-CD3 stimulation of CD8 lymphocytes; in males Signal 
Lymphocyte Activating Molecule Associated Protein (SAP), and X-linked Inhibitor of 
Apoptosis Protein (XIAP) expression).[40]  In this group 3/21 (14%) ultimately had a 
diagnosis of primary HLH and the authors therefore recommend screening in all 
children whose first rheumatologic presentation is with MAS. 
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TREATMENT 
Details of the treatments for HLH/MAS are beyond the scope of this review.  In broad 
terms, however, primary and secondary HLH, with the exception of MAS, are treated 
according to the HLH-2004 guidelines with an 8-week induction period of 
dexamethasone, etoposide and ciclosporin and intrathecal methotrexate and 
steroids in selected patients with CNS involvement.[30]  In time, etoposide 
chemotherapy may be replaced by use of the anti-T-cell antibody Alemtuzumab if a 
multicentre prospective study being conducted in France shows equal or improved 
efficacy (personal communication, Dr Despina Moshous).  Continued chemotherapy 
and haematopoietic stem cell transplantation using reduced intensity conditioning 
therapy is recommended for genetic, familial and persistently active disease.  In 
resolved, non-familial, non-genetic disease, treatment may be stopped after the 
initial 8-week period.  High-dose intravenous methylprednisolone is the commonest 
first-line treatment for MAS with ciclosporin or intravenous immunoglobulin added in 
patients not responding rapidly to steroids.[4]  In all cases, adequate anti-microbial 
therapy is important both to treat an identified infectious trigger and if there is 
ongoing diagnostic uncertainty between severe systemic sepsis and HLH.  In the 
case of EBV-associated HLH, depletion of B lymphocytes using the monoclonal 
antibody rituximab in combination with steroids, etoposide and/or ciclosporin 
chemotherapy has been shown to be effective.[41] 
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CONCLUSION 
HLH is a potentially life-threatening syndrome which may present, particularly in 
young children, as a result of genetic mutations or being triggered by infections, 
malignancy or rheumatic disease.  Early recognition and instigation of appropriate 
treatment is crucial to prevent a cytokine storm progressing to cause multi-organ 
failure.  Increased awareness of the condition is the first step, together with 
knowledge of the key features including persistent fever, cytopenias and extreme 
hyperferritinaemia.  Children with HLH often require high dependency / intensive 
care and collaborative working between specialists is essential to maximise chances 
of a favourable outcome. 
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FIGURE LEGENDS 
 
Figure 1: Suggested algorithm for investigation of suspected 
haemophagocytic lymphohistiocytosis (HLH) 
 
Legend: HLH, haemophagocytic lymphohistiocytosis; LDH, lactate dehydrogenase; NK, 
natural killer cell 
 
 
Figure 2: Algorithm for identification of genetic causes of haemophagocytic 
lymphohistiocytosis (HLH)   
The HLH algorithm based on the flow cytometric assays: All the patients fitting into HLH 
criteria, irrespective of age and clinical presentations, should be screened for perforin 
expression and granule release assay.  All male patients should be screened for SAP and 
XIAP expression.  For patients clinically presenting with albinism, microscopic analysis of 
hair and blood smear is essential for differential diagnosis of Chediak Higashi syndrome, 
Griscelli syndrome and Hermansky Pudlak syndrome.  Based on the defect in expression of 
a particular protein identified, molecular characterisation for the respective gene should be 
performed for confirmation of diagnosis. 
Reproduced from Indian J Pediatr, 83, 434-443 (2016), Madkaikar et al. with permission of 
Springer.[17]  
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